Uterine sarcomas: Have we made any progress?

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 1, 2004, Pages 1-4

  O'Meara, Anne T ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GESTAGEN; GONADORELIN AGONIST; IFOSFAMIDE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; THALIDOMIDE;

AGE; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; DATA ANALYSIS; DRUG ACTIVITY; EDITORIAL; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MULTIVARIATE ANALYSIS; NONHUMAN; NULLIPARA; OBESITY; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; UTERUS SARCOMA;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIAGNOSTIC TECHNIQUES, OBSTETRICAL AND GYNECOLOGICAL; FEMALE; HUMANS; PROGNOSIS; RISK FACTORS; SARCOMA; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 1242272144     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200402000-00002     Document Type: Editorial

References (25)

1. Brooks SE, Zhan M, Cote TR, et al. Ethnic differences in incidence, treatment and survival: SEER analysis of 1175 cases of uterine sarcoma [abstract]. Gynecol Oncol 2002; 84:481a.
2. Salazar OM. Uterine sarcomas: natural history, treatment and prognosis. Cancer 1978; 42:1152.
3. El Husseiny G, Al Bareedy N, Mourad WA, et al. Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol (CCT) 2002; 25:256-260.
4. Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20:2758-2760.
5. Kawamura N, Ichimura T, Ito F, et al. Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma. Cancer 2002; 94:1713-1720.
6. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomography with 18F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001; 80:372-377.
7. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001; 39:273-278.
8. Oliva E, Young RH, Amin MB, Clement PB. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002; 26:403-412.
9. Giuntoli RL, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003; 89:460-469.
10. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002; 20:791-796.
11. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002; 55:321-325.
12. Lancaster JM, Risinger JI, Carney ME, et al. Mutational analysis of the PTEN gene in human uterine sarcomas. Am J Obstet Gynecol 2001; 184:1051-1053.
13. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol 2001; 27:282-285.
14. Echt G, Jepson J, Steel J, et al. Treatment of uterine sarcomas. Cancer 1990; 66:35-39.
15. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986; 12:2127-2130.
16. Tierney J. Adjuvant chemotherapy for localized respectable soft tissue sarcoma of adults. The Cochrane Database of Systemic Reviews. The Cochrane Library 1999; 2:1-30.
17. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a gynecologic oncology group study. J Clin Oncol 1985;3:1240-1245.
18. Gallup DG, Blessing JA, Andersen W, Morgan MA. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2003; 89:48-51.
19. Hensley ML, Maki R, Benkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20:2824-2831.
20. Cadron I, Amant F, Berteloot P, et al. The importance of hormones in the treatment of endometrial stromal sarcoma: an update [abstract]. Int J Gynecol Cancer 2003; 13:70a.
21. Emoto M, Ishiguro M, Iwasaki H, et al. Effect of angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice. Gynecol Oncol 2003; 89:88-94.
22. Welcker M, Lukas J, Strauss M, Bartek J. Enhanced protein stability: a novel mechanism of D-type cyclin over-abundance identified in human sarcoma cells. Oncogene 1996; 13:419-425.
23. Amant F, Dorfling CM, Dreyer L, et al. Microsatellite instability in uterine sarcomas. Int J Gynecol Cancer 2001; 11:218-223.
24. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-kit oncoprotein: biological and clinical implications. Oncogene 2001; 20:5054-5058.
25. Wang L, Felix JC, Lee JL, et al. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol Oncol 2003; 90:402-406.